CompuGroup stock holds steady as investors await late-July earnings update

CompuGroup Medical SECo (DE000A288904) stock is quoted at EUR 16.22 on the London Stock Exchange as of June 27, 2026, with the price unchanged during that session per market data. Recent quote information for the Compugroup Medical listing on the London market indicates that the shares closed at EUR 16.22 and did not move on the day, giving investors a stable starting point as they look ahead to the companys next set of results.

According to the same market overview as of June 27, 2026, CompuGroup Medicals market capitalization stands at EUR 1.23 billion, reflecting how the stock market currently values the companys health IT business. The data also show a 52-week trading range between EUR 16.22 and EUR 28.05, meaning the June 27, 2026 closing price sits at the bottom end of the stocks one-year band and roughly EUR 11.83 below the 52-week high, a sizable gap that underscores the room for potential recovery if fundamentals improve.

Dividend yield and earnings power

The same equity snapshot lists a dividend yield of 3.08 percent for CompuGroup Medical based on the current share price and the most recently declared annual dividend as of June 27, 2026. That yield offers investors a modest income stream and can be used as one lens for comparing the stock with other European technology and healthcare names. With the stock at EUR 16.22 and a 3.08 percent yield, the implied annual dividend payment corresponds to roughly EUR 0.50 per share, giving a sense of the cash returned to shareholders in the latest fiscal year.

The profile also reports earnings per share on a trailing twelve-month basis of EUR 0.54 as of June 27, 2026. That figure means the stock trades at a price-to-earnings ratio of close to 30 when dividing the EUR 16.22 share price by EUR 0.54 of trailing earnings, which places CompuGroup Medical in a valuation bracket often associated with growth-oriented software and services businesses. For investors, the combination of a double-digit price-to-earnings multiple and a mid-single-digit dividend yield highlights a balance between reinvestment for growth and shareholder returns.

Ownership and institutional interest

The same market data page provides a detailed breakdown of ownership that sheds light on who holds CompuGroup Medical shares as of late June 2026. Mutual funds and exchange-traded funds collectively own 785,060 shares, equivalent to 1.52 percent of the shares outstanding, with an associated market value of EUR 21.35 million at the represented price level. Other institutional investors account for 34.38 million shares, or 66.45 percent of the equity, valued at EUR 935.05 million, while public companies and individual investors hold 16.57 million shares, or 32.03 percent, worth EUR 450.78 million.

In total, the ownership overview shows 51.73 million shares outstanding, with a combined market value of EUR 1.41 billion, slightly above the EUR 1.23 billion market cap figure cited earlier for June 27, 2026. The difference between those two values can reflect different dates or rounding conventions in the data, but both numbers confirm that CompuGroup Medical is a mid-cap player in the European health IT space rather than a small niche provider. For portfolio managers, the high share of institutional holdings implies that professional investors have taken a strong interest in the stock, which can support liquidity and coverage.

Upcoming earnings date and expectations

The same equity summary notes that CompuGroup Medical will release its next earnings report on July 30, 2026, giving investors a clear calendar marker for the next fundamental update. With the most recent trailing earnings per share at EUR 0.54 and the stock trading at EUR 16.22 as of June 27, 2026, the upcoming report will be an important test of whether profit growth can justify the current valuation and potentially close part of the gap to the EUR 28.05 52-week high. Investors tracking the stock can use that July 30, 2026 earnings date to align their expectations around revenue growth, margin development and any updates to guidance.

While the available market data do not list detailed quarterly revenue or operating income figures within the last nine months, the trailing twelve-month earnings per share of EUR 0.54 as of June 27, 2026 still provide a fresh indicator of profitability. When annualized, that level of earnings suggests that CompuGroup Medicals net income has stayed positive over the latest year, supporting the dividend and reinforcing the companys ability to invest in product development and customer solutions. The earnings trajectory around the July 30, 2026 report will therefore matter for investors assessing whether the stock deserves to move closer to its historical highs or remains anchored near the 52-week low.

Valuation context and peer comparison

With CompuGroup Medical trading at EUR 16.22 and a trailing earnings per share of EUR 0.54 as of June 27, 2026, the implied price-to-earnings multiple of around 30 places the stock in a premium bracket relative to many traditional healthcare providers, which often trade at lower earnings multiples. Such a valuation is more typical of software and digital health companies where investors expect sustained growth in subscription revenue, recurring service contracts and cross-selling of solutions. The 3.08 percent dividend yield at this price level adds an income component that some pure-play software firms do not offer, making CompuGroup Medical somewhat hybrid in its profile.

For comparison, the reported 52-week high of EUR 28.05 shows that at the top of the one-year trading band the stock commanded a price-to-earnings multiple exceeding 50 based on the same EUR 0.54 trailing earnings. That higher historical valuation underscores how sensitive the shares can be to changes in growth expectations and risk appetite. The current gap of EUR 11.83 between the June 27, 2026 closing price and the 52-week high suggests that either fundamentals have softened or investor sentiment has cooled, and the upcoming July 30, 2026 earnings release could act as a catalyst to either narrow or widen that distance.

CompuGroup Medical software platform

A central element of CompuGroup Medicals business model is its comprehensive software platform for doctors, hospitals and other healthcare providers, which integrates electronic health records, practice management tools and billing systems. These solutions are typically delivered on a subscription basis, generating recurring revenue that contributes to the trailing earnings per share of EUR 0.54 reported as of June 27, 2026. By offering modules for appointment scheduling, clinical documentation and telemedicine, the platform aims to reduce administrative burden and improve the flow of medical information across different settings.

CompuGroup Medical also provides interoperability solutions that help connect laboratory information systems, pharmacies and insurance payers, enabling smoother data exchange within national healthcare systems. Such products are often tailored to specific regulatory environments in Europe and other regions, which supports long-term contracts and stable cash flows. The dividend yield of 3.08 percent at the June 27, 2026 share price of EUR 16.22 indicates that management has chosen to share a portion of these cash flows with shareholders, while retaining enough earnings to invest in new modules and cloud-based offerings.

Stock perspective and current price level

From a stock perspective, CompuGroup Medicals June 27, 2026 closing price of EUR 16.22 on the London Stock Exchange places it at the bottom of its 52-week range and well below the EUR 28.05 high, highlighting a cautious market stance ahead of the July 30, 2026 earnings report. The companys trailing earnings per share of EUR 0.54 and dividend yield of 3.08 percent at that price show that it remains profitable and continues to return cash to shareholders, even as investors demand clearer evidence of growth to re-rate the shares.